Send the following on WhatsApp
Continue to Chathttps://oncoletter.ch/share/?p=twitter&u=https%3A%2F%2Foncoletter.ch%2Fkongressberichte-videos-slides-Onkologie%2Fesmo-2014-madrid-26-30-september-2014%2Fcaroline-robert-gustave-roussy-france.html&t=COMBI-v%3A%20A%20randomised%2C%20open-label%2C%20Phase%20III%20study%20comparing%20the%20combination%20of%20dabrafenib%20%28D%29%20and%20trametinib%20%28T%29%20with%20vemurafenib%20%28V%29%20as%20first-line%20therapy%20in%20patients%20%28pts%29%20with%20unresectable%20or%20metastatic%20BRAF%20V600E%2FK%20mutation-positive%20cutaneous%20melanom